7 Feb 2013 07:03
Press Release | 7 February 2013 |
LiDCO Group Plc
("LiDCO" or the "Company")
Launch and first sales of the LiDCOrapid v2 with Unity software in Europe
LiDCO Group Plc (AIM: LID), the cardiovascular monitoring company, is pleased to announce the LiDCOrapid v2 with Unity software has now achieved the CE mark allowing sales in Europe to commence. First sales have already been made to both customers in the UK and to our European distributor network.
LiDCO's commitment to parameter integration has resulted in the development of a new generation monitor for the hemodynamic monitoring of surgical patients. The LiDCOrapid v2 with Unity software is the first monitor in the world to be designed specifically for multi-parameter monitoring of both depth of anesthesia and fluids.
LiDCO's Unity software allows the connection of two modules to the LiDCOrapid v2 to co-display Covidien's depth of anesthesia parameter (BIS) and CNSystem's continuous non-invasive blood pressure monitoring (CNAPTM). Through parameter integration this new generation of monitor addresses a growing demand for multi-parameter monitors that can reduce the number of single parameter monitors by the bedside. Additional parameters can now easily be added to Unity software to further increase the breadth of monitoring available on the LiDCOrapid platform.
The LiDCOrapid v2 with Unity software satisfies both the NICE recommendations for the monitoring of fluids and depth of anesthesia in certain high risk surgery patients. The NHS in England will be providing payment incentives aiming to significantly increase the numbers of surgery patients that are monitored in this way.
Dr Terry O'Brien, CEO of LiDCO, commented: "LiDCO is already seeing significant growth in sales of its surgery monitoring products. Our new product has arrived at a timely point anticipating both the UK NHS's drive for better care of high risk surgery patients and recent NICE recommendations for the adoption of advanced fluid and depth of anesthesia monitoring.
"We expect the availability of this new product will increase high margin disposable use in our existing and the future installed base of LiDCOrapid monitors. Existing LiDCOrapids are easily upgraded to provide the new functionality.
"We estimate continuous non-invasive fluid and depth of anesthesia monitoring could take the worldwide surgery market potential for our products to approximately 10.5 million patients per annum with a potential disposable revenue stream of US$1.72 billion per annum."
- ENDS -
For further information, please contact:
LiDCO Group Plc | |
Terry O'Brien (CEO) | Tel: +44 (0)20 7749 1500 |
Paul Clifford (Finance Director) | |
John Rowland (Company Secretary) | www.lidco.com |
FinnCap | |
Geoff Nash / Henrik Persson Stephen Norcross (broking) | Tel: +44 (0)20 7600 1658 www.finncap.com |
Media enquiries:
Abchurch | |
Adam Michael / Simone Elviss / Jamie Hooper | Tel: +44 (0) 20 7398 7719 |
Jamie.hooper@abchurch-group.com | www.abchurch-group.com |
About LiDCO Group Plc
LiDCO is a supplier of minimally invasive hemodynamic equipment to hospitals, to monitor the amount of blood flowing around the body and ensure that vital organs are adequately oxygenated. LiDCO's products facilitate the application of hemodynamic optimisation protocols for high risk patients in both critical care units and in the operating theatre.
Increasingly clinical studies are showing that the optimisation of patients' hemodynamic status in high risk patients produces better outcomes and reduced hospital stay. LiDCO's computer-based technology, developed at St Thomas' Hospital in London, has been shown to significantly reduce morbidity and complications, length of stay and overall costs associated with major surgery.
Key Products:
LiDCOplus: a computer-based platform monitor used in the Intensive Care Unit for real-time continuous display of hemodynamic parameters including cardiac output, oxygen delivery and fluid-volume responsiveness (PPV% and SVV%) | |
LiDCOrapid: a cardiac output monitor designed specifically for use in the operating theatre for fluid and drug management. The monitor enables anesthetists to get accurate and immediate feedback on the patient's fluid and hemodynamic status - a key measure of overall well-being before, during and after surgery. The LiDCOrapid provides: | |
·; | early and rapid warning of hemodynamic change to aid choice of therapeutic route: fluid or drug |
·; | quantification of hemodynamic response, |
·; | guidance on effective delivery of fluids to ensure the right amount at the right time |
LiDCOview: an easy-to-use graphical display of historical LiDCOplus and LiDCOrapid hemodynamic data. | |
All LiDCO monitors use single-patient disposables (sensors or smartcards) which provide an ongoing revenue stream.
LiDCO Distribution Network:
LiDCO's strategy is to sell directly to hospitals in the UK, and through a network of specialty critical care and anesthesia distributors in the rest of the world.
LiDCO's sales office is in Cambridge, its manufacturing facility and headquarters are in London and its shares are traded on AIM. For more information please see www.lidco.com.
Notes
BISand Bispectral Index are trademarks of Covidien LP registered in the U.S. and foreign countries, for more information on BIS products see: www.covidien.com
CNAPTM is a trademark of CNSystems Medizintechnik AG, for more information see: www.cnsystems.at